Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of YYC405-T Added to Metformin and Dapagliflozin in Type 2 Diabetes
NCT05226897Phase 3Unknown
- Sponsor
- Yooyoung Pharmaceutical
- Start
- Jul 2021
- Primary completion
- Oct 2022
- Countries
- 1
01
Overview
A Phase 3 trial of YYC405-T in type 2 diabetes mellitus (T2DM), sponsored by Yooyoung Pharmaceutical. Status: unknown.
02
Drugs
YYC405-T
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05226897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05226897.